Reference
Brannigan J, et al. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation 7: No. 5, Sep 2020. Available from: URL: http://doi.org/10.1212/NXI.0000000000000799
Rights and permissions
About this article
Cite this article
Alemtuzumab/methylprednisolone. Reactions Weekly 1880, 27 (2021). https://doi.org/10.1007/s40278-021-04861-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-04861-1